{"id":522458,"date":"2021-08-03T16:11:51","date_gmt":"2021-08-03T20:11:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/"},"modified":"2021-08-03T16:11:51","modified_gmt":"2021-08-03T20:11:51","slug":"eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/","title":{"rendered":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PALO ALTO, Calif.<\/span>, <span class=\"xn-chron\">Aug. 3, 2021<\/span> \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that <span class=\"xn-person\">David Cory<\/span>, President and CEO, will participate in two investor conference events in August:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" title=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" alt=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>\n          <i>BTIG Virtual Healthcare Conference 2021<\/i>\n        <\/li>\n<ul type=\"circle\">\n<li>\n            <i>Fireside chat<\/i>\n          <\/li>\n<li>\n            <i><br \/>\n              <span class=\"xn-chron\">Tuesday, August 10<\/span> at 1:00 PM ET\u00a0<\/i>\n          <\/li>\n<\/ul>\n<li>\n          <i>2021 Wedbush PacGrow Healthcare Virtual Conference<\/i>\n        <\/li>\n<ul type=\"circle\">\n<li>\n            <i>&#8220;Live-r Let Die \u2013 Updates in Liver Disease&#8221; panel discussion<\/i>\n          <\/li>\n<li>\n            <i><br \/>\n              <span class=\"xn-chron\">Tuesday, August 10<\/span> at <span class=\"xn-chron\">2:20 PM ET<\/span><\/i>\n          <\/li>\n<\/ul>\n<\/ul>\n<p>Eiger will also host one-on-meetings with investors at both conferences.\u00a0 <\/p>\n<p>A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3248284-1&amp;h=199876874&amp;u=http%3A%2F%2Fwww.eigerbio.com%2F&amp;a=www.eigerbio.com\" rel=\"nofollow noopener\">www.eigerbio.com<\/a> in the Investors section.\u00a0 A replay of the webcast will be available approximately one hour following the live event.<\/p>\n<p>\n        <b>About Eiger<br \/><\/b>Eiger\u00a0is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.<\/p>\n<p>Eiger&#8217;s\u00a0lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. \u00a0Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.\u00a0 Peginterferon Lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.<\/p>\n<p>Zokinvy<sup>\u00ae<\/sup>\u00a0for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company&#8217;s first FDA approved product.\u00a0 A Marketing Authorization Application (MAA) is under review by the\u00a0European Medicines Agency\u00a0(EMA).<\/p>\n<p>For additional information about\u00a0Eiger\u00a0and its clinical programs, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3248284-1&amp;h=3094860767&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3236964-1%26h%3D1435227949%26u%3Dhttp%253A%252F%252Fwww.eigerbio.com%252F%26a%3Dwww.eigerbio.com&amp;a=www.eigerbio.com\" rel=\"nofollow noopener\">www.eigerbio.com<\/a>.<\/p>\n<p>\n        <b>Investors and Media:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Charles Butler<\/span> \u2013 VP, Investor Relations and Corporate Communications<br \/>Email:\u00a0<a target=\"_blank\" href=\"mailto:cbutler@eigerbio.com\" rel=\"nofollow noopener\">cbutler@eigerbio.com<\/a><br \/>Phone: 1-650-272-6138<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE63759&amp;sd=2021-08-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences-301347526.html\">https:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences-301347526.html<\/a><\/p>\n<p>SOURCE  Eiger BioPharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE63759&amp;Transmission_Id=202108031605PR_NEWS_USPR_____NE63759&amp;DateId=20210803\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PALO ALTO, Calif., Aug. 3, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate in two investor conference events in August: BTIG Virtual Healthcare Conference 2021 Fireside chat Tuesday, August 10 at 1:00 PM ET\u00a0 2021 Wedbush PacGrow Healthcare Virtual Conference &#8220;Live-r Let Die \u2013 Updates in Liver Disease&#8221; panel discussion Tuesday, August 10 at 2:20 PM ET Eiger will also host one-on-meetings with investors at both conferences.\u00a0 A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.\u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522458","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PALO ALTO, Calif., Aug. 3, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate in two investor conference events in August: BTIG Virtual Healthcare Conference 2021 Fireside chat Tuesday, August 10 at 1:00 PM ET\u00a0 2021 Wedbush PacGrow Healthcare Virtual Conference &#8220;Live-r Let Die \u2013 Updates in Liver Disease&#8221; panel discussion Tuesday, August 10 at 2:20 PM ET Eiger will also host one-on-meetings with investors at both conferences.\u00a0 A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.\u00a0 &hellip; Continue reading &quot;Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T20:11:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences\",\"datePublished\":\"2021-08-03T20:11:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/\"},\"wordCount\":300,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/\",\"name\":\"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"datePublished\":\"2021-08-03T20:11:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk","og_description":"PR Newswire PALO ALTO, Calif., Aug. 3, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate in two investor conference events in August: BTIG Virtual Healthcare Conference 2021 Fireside chat Tuesday, August 10 at 1:00 PM ET\u00a0 2021 Wedbush PacGrow Healthcare Virtual Conference &#8220;Live-r Let Die \u2013 Updates in Liver Disease&#8221; panel discussion Tuesday, August 10 at 2:20 PM ET Eiger will also host one-on-meetings with investors at both conferences.\u00a0 A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.\u00a0 &hellip; Continue reading \"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T20:11:51+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences","datePublished":"2021-08-03T20:11:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/"},"wordCount":300,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/","name":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","datePublished":"2021-08-03T20:11:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-participate-in-upcoming-august-2021-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522458"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522458\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}